AmerisourceBergen to Acquire PharmaLex for $1.28 Billion
Leading U.S. drug wholesaler AmerisourceBergen is expanding its global biopharma services with the purchase of Frankfurt, Germany-based PharmaLex for $1.28 billion in cash.
The acquisition will broaden the U.S. company’s international reach in services ranging from clinical development consulting to marketing authorization. PharmaLex’s scientific, regulatory and safety and compliance experts provide regulatory support to biopharma companies throughout a product’s lifecycle.
AmerisourceBergen CEO Steven H. Collis said the purchase will advance the company’s role as a strategic partner for “end-to-end clinical and commercial enablement solutions.”
The acquisition is expected to close by March 2023.